News

AstraZeneca’s Forxiga recommended for approval in the EU by CHMP for heart failure

23 October 2020 | 5:25 am
Mene Pangalos
AstraZeneca’s Forxiga (dapagliflozin) has been recommended for an indication extension of its marketing authorisation in the European Union (EU) for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF) in adults with and without type-2 diabetes (T2D). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its […]
News

AstraZeneca’s Trixeo Aerosphere recommended for approval in the EU by CHMP

22 October 2020 | 7:29 am
AstraZeneca scientist
AstraZeneca’sTrixeo Aerosphere (formoterol fumarate/glycopyrronium bromide/budesonide) has been recommended for marketing authorisation in the European Union (EU) for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA), or a combination of a LABA and a long-acting […]
News

Oncopeptides has submitted an IND application to FDA

21 October 2020 | 5:07 am
Marty Duvall
Oncopeptides has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA), for OPD5 – a second drug candidate based on the Peptide Drug Conjugate platform (PDC). Oncopeptides plans to initiate clinical development of OPD5 with an open-label phase 1, dose escalation study on safety and tolerability of OPD5 as […]
News

10 million SEK awarded to research on myelodysplastic syndrome

21 October 2020 | 4:56 am
Hellstrom_Tobiasson
The Tobias Foundation grant in 2020 has been awarded to Magnus Tobiasson and Eva Hellström Lindberg, Karolinska Institutet. The grant amounts to SEK 10 million over a five-year period. It will support research on early detection of relapse after stem cell transplantation for patients with myelodysplastic syndrome. “The generous grant from the Tobias Foundation enables […]
News

Nanoform starts first-in-human trial

20 October 2020 | 2:47 pm
Nanoform
Nanoform will, in the fourth quarter of 2020, start the first ever human trial of a drug candidate nanoformed using its CESS technology. Dosing will begin before year-end 2020 (previously: in 2021) and results are expected before the end of Q2/2021. The clinical trial is a progression of Nanoform’s first GMP campaign, which the company […]
News

SEK 3.1 billion to data-driven life science in Sweden

20 October 2020 | 2:09 pm
data driven life science
Knut and Alice Wallenberg Foundation (KAW) donates SEK 3.1 billion to a new research initiative focusing on data-driven life science (DDLS). The most recent life science initiative from KAW consists of two parts, where one part is a completely new national investment in computer-driven life science with SEK 3.1 billion over twelve years. The second […]
News

Bactiguard among the most equal listed Swedish companies

20 October 2020 | 1:38 pm
Cecilia Edström
Bactiguard advances to Allbright’s green list, including the most equal listed Swedish companies. With a female CEO, 50 percent women in the management team and two female board members, Bactiguard climbs from position 132 to 57 among 329 listed companies. “During the year, 20 companies advanced from Allbright’s yellow list to the equal green list. […]
News

Medicon Valley aims to become a global centre for microbiome research

19 October 2020 | 10:41 am
microbiome research
A new project seeks to build on the cluster’s strengths by positioning it as a global centre for microbiome research. The Microbiome Signature Project aims to strengthen entry into the Greater Copenhagen region’s research environment within microbiome research through enhancing collaboration and synergies cross border and cross disciplines. It will also seek to boost private […]
News

Ultimovacs announces Phase I data

19 October 2020 | 9:26 am
Carlos de Sousa
Ultimovacs has announced five-year overall survival data from the Phase I trial evaluating UV1 as maintenance therapy in patients with non-small cell lung cancer. The results confirm achievement of the primary endpoints of safety and tolerability and indicate encouraging initial signals of long-term survival benefit. “Ultimovacs has established a growing body of clinical data demonstrating […]
News

Oncopeptides signs 40 million EUR loan agreement

19 October 2020 | 9:14 am
Anders Martin-Löf
Oncopeptides has entered into a loan agreement with the European Investment Bank (EIB), granting the company access to an unsecured loan facility of up to 40 million EUR. The loan may be used to further support the clinical development of melflufen, and the company’s transition from a R&D company into a fully integrated global biopharmaceutical […]